Company Filing History:
4 out of 5,450 
2 out of 5 
1 out of 2,009 
Years Active: 2016-2021
Title: Amy Heimberger: Innovator in Oncolytic Virus Therapy
Introduction
Amy Heimberger is a prominent inventor based in Houston, Texas, known for her significant contributions to the field of cancer therapy. With a total of four patents to her name, she has focused her research on biomarkers and combination therapies that utilize oncolytic viruses and immunomodulation. Her work aims to improve patient outcomes in cancer treatment.
Latest Patents
Heimberger's latest patents revolve around the identification of biomarkers that are crucial for the prognosis, selection, and monitoring of oncolytic virus therapy in cancer patients. These inventions provide insights into the expression patterns of proteins that can predict the effectiveness of oncolytic virus therapy. Furthermore, her patents include methods for identifying cancer patients who may not respond to this type of therapy, allowing for the co-administration of agents that stimulate a cell-mediated immune response or alternative therapies.
Career Highlights
Throughout her career, Amy Heimberger has worked with notable organizations, including the University of Texas System and Dnatrix, Inc. Her innovative research has positioned her as a leader in the field of cancer therapy, particularly in the application of oncolytic viruses.
Collaborations
Heimberger has collaborated with esteemed colleagues such as Frank Tufaro and Charles A. Conrad, contributing to the advancement of cancer treatment methodologies.
Conclusion
Amy Heimberger's work in the realm of oncolytic virus therapy and biomarkers represents a significant advancement in cancer treatment. Her innovative patents and collaborations highlight her dedication to improving patient care and outcomes in oncology.